RU2020113679A - Лекарственная композиция, включающая ингибитор sglt-2 и блокатор рецептора ангиотензина - Google Patents
Лекарственная композиция, включающая ингибитор sglt-2 и блокатор рецептора ангиотензина Download PDFInfo
- Publication number
- RU2020113679A RU2020113679A RU2020113679A RU2020113679A RU2020113679A RU 2020113679 A RU2020113679 A RU 2020113679A RU 2020113679 A RU2020113679 A RU 2020113679A RU 2020113679 A RU2020113679 A RU 2020113679A RU 2020113679 A RU2020113679 A RU 2020113679A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- sglt
- inhibitor
- receptor blocker
- angiotensin receptor
- Prior art date
Links
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 title claims 3
- 229940125364 angiotensin receptor blocker Drugs 0.000 title claims 3
- 239000000203 mixture Substances 0.000 title claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 206010020772 Hypertension Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical group C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 claims 1
- 239000005480 Olmesartan Substances 0.000 claims 1
- 229960003834 dapagliflozin Drugs 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229960005117 olmesartan Drugs 0.000 claims 1
- 150000004102 olmesartan derivatives Chemical group 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (7)
1. Фармацевтическая композиция, включающая ингибитор SGLT-2 и блокатор рецептора ангиотензина.
2. Фармацевтическая композиция по п. 1, где ингибитор SGLT-2 представляет собой дапаглифлозин или его фармацевтически приемлемую соль или сольват.
3. Фармацевтическая композиция по п. 1 или 2, где блокатор рецептора ангиотензина представляет собой олмесартан или его фармацевтически приемлемую соль или его фармацевтически приемлемый сложный эфир.
4. Фармацевтическая композиция по п. 3, где фармацевтическая композиция представляет собой композицию для лечения гипертензии.
5. Фармацевтическая композиция по п. 4, где Фармацевтическая композиция представляет собой композицию для лечения гипертензии и диабета.
6. Фармацевтическая композиция по п. 4, где фармацевтическая композиция предназначена для введения пациентам с гипертензией или пациентам и с гипертензией и с диабетом.
7. Фармацевтическая композиция по п. 4, где фармацевтическая композиция представляет собой твердую лекарственную форму.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2017-0120311 | 2017-09-19 | ||
| KR20170120311 | 2017-09-19 | ||
| KR10-2018-0075025 | 2018-06-28 | ||
| KR1020180075025A KR101943382B1 (ko) | 2017-09-19 | 2018-06-28 | Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물 |
| PCT/KR2018/010110 WO2019059557A2 (ko) | 2017-09-19 | 2018-08-31 | Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2020113679A3 RU2020113679A3 (ru) | 2021-10-20 |
| RU2020113679A true RU2020113679A (ru) | 2021-10-20 |
| RU2778313C2 RU2778313C2 (ru) | 2022-08-17 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| JP6993502B2 (ja) | 2022-01-13 |
| JP2020534347A (ja) | 2020-11-26 |
| BR112020004107A2 (pt) | 2020-09-24 |
| RU2020113679A3 (ru) | 2021-10-20 |
| CN110520133A (zh) | 2019-11-29 |
| WO2019059557A3 (ko) | 2019-05-09 |
| US10980822B2 (en) | 2021-04-20 |
| KR101943382B1 (ko) | 2019-01-29 |
| US20200054656A1 (en) | 2020-02-20 |
| MX2020003088A (es) | 2020-08-17 |
| WO2019059557A2 (ko) | 2019-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200800881A1 (ru) | Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами | |
| FI4212152T3 (fi) | Sakubitriili-valsartaaniannostusohjelma kroonisen systolisen sydämen vajaatoiminnan hoitoon | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| RU2014111069A (ru) | Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение | |
| WO2020115555A3 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| RU2015104537A (ru) | Способы лечения стромальных опухолей желудочно-кишечного тракта | |
| JP2010530376A5 (ru) | ||
| PH12021550687A1 (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt | |
| PH12018500432A1 (en) | Heteroaryl compounds and their use as therapeutic drugs | |
| MY206893A (en) | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof | |
| FI3383385T4 (fi) | Melflufeeniannoskuureja syöpään | |
| RU2019112148A (ru) | Фармацевтическая композиция и способ лечения неалкогольной жировой болезни печени | |
| AR115913A1 (es) | Formas de dosificación oral biodisponibles, uso, métodos | |
| JP2007119497A5 (ru) | ||
| PH12019500516A1 (en) | Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof | |
| RU2007132971A (ru) | Способы и материалы с транс-кломифеном для лечения мужского бесплодия | |
| RU2020113679A (ru) | Лекарственная композиция, включающая ингибитор sglt-2 и блокатор рецептора ангиотензина | |
| RU2016103099A (ru) | Способ предотвращения и/или лечения хронической травматической энцефалопатии - i | |
| RU2012136190A (ru) | Фармацевтический состав для профилактики или лечения артрозоартрита, содержащий ребамипид в качестве активного ингредиента | |
| TN2012000568A1 (en) | Sustained-release therapeutic agent for hypertension and renal dysfunction | |
| EA201991359A1 (ru) | Фармацевтические лекарственные формы | |
| JP2017509683A5 (ru) | ||
| EP4052699A4 (en) | MEDICINE IN SOLID PHARMACEUTICAL FORM ADMINISTERED ORALLY | |
| RU2016143153A (ru) | Комбинации противораковых лекарств | |
| IL275091B1 (en) | Methods for treating gaucher disease |